Table 1.
Published trials of immune checkpoint inhibitors.
| Author | Phase | Intervention | Patient Population | Disease State | Outcomes |
|---|---|---|---|---|---|
| Davis et al. 2016 [61] | I/IIb | Ipilimumab | AML, NHL, HL, CML, CLL, MM, MPN, AL | Relapsed after Allo-HSCT | CR: 23% (5/28) PR: 9% (2/22) |
| Daver et al. 2016 [62] | I/IIb | Nivolumab + Azacitidine | AML | Relapsed after prior therapy | CR: 18% (6/51) HI: 15% (5/51) |
| Lindblad et al. 2018 | I/II | Pembrolizumab + decitabine | AML | Relapsed after prior therapy | CR: 10% (1/10) SD:40% (4/10) |
| Daver et al. 2018 [63] | II | Nivolumab + Azacitidine + Ipilimumab | AML | R/R | CR/CRi: 36% (6/20) Prolonged SD:10% (2/20) |
| Ravandi et al. 2019 [64] | II | Idarubicin + Cytarabine + Nivolumab | AML and high risk MDS | Newly diagnosed | CR:/CRi 78% (34/44) Negative MRD: 41% (18/34) |